CL2013002739A1 - Compuesto macrociclicos analogo de sangliferina, inhibidor de la ciclofilina; forma cristalina solida y forma de polimorfo cristalino; procedimientos para prepararlos; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como vhc o vih o uso como inmunosupresor o agente antiinflamatorio. - Google Patents
Compuesto macrociclicos analogo de sangliferina, inhibidor de la ciclofilina; forma cristalina solida y forma de polimorfo cristalino; procedimientos para prepararlos; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como vhc o vih o uso como inmunosupresor o agente antiinflamatorio.Info
- Publication number
- CL2013002739A1 CL2013002739A1 CL2013002739A CL2013002739A CL2013002739A1 CL 2013002739 A1 CL2013002739 A1 CL 2013002739A1 CL 2013002739 A CL2013002739 A CL 2013002739A CL 2013002739 A CL2013002739 A CL 2013002739A CL 2013002739 A1 CL2013002739 A1 CL 2013002739A1
- Authority
- CL
- Chile
- Prior art keywords
- hcv
- hiv
- intermediary
- procedures
- prepare
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 239000003018 immunosuppressive agent Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- 229940122806 Cyclophilin inhibitor Drugs 0.000 title 1
- 229940121363 anti-inflammatory agent Drugs 0.000 title 1
- 239000002260 anti-inflammatory agent Substances 0.000 title 1
- 239000000134 cyclophilin inhibitor Substances 0.000 title 1
- 229960003444 immunosuppressant agent Drugs 0.000 title 1
- 230000001861 immunosuppressant effect Effects 0.000 title 1
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1105293.3A GB201105293D0 (en) | 2011-03-29 | 2011-03-29 | Novel compounds and methods for their production |
| GBGB1113629.8A GB201113629D0 (en) | 2011-08-08 | 2011-08-08 | Novel compounds and methods for their production |
| GBGB1202060.8A GB201202060D0 (en) | 2012-02-07 | 2012-02-07 | Novel compounds and methods for their production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013002739A1 true CL2013002739A1 (es) | 2014-07-11 |
Family
ID=46001313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013002739A CL2013002739A1 (es) | 2011-03-29 | 2013-09-25 | Compuesto macrociclicos analogo de sangliferina, inhibidor de la ciclofilina; forma cristalina solida y forma de polimorfo cristalino; procedimientos para prepararlos; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como vhc o vih o uso como inmunosupresor o agente antiinflamatorio. |
| CL2013002740A CL2013002740A1 (es) | 2011-03-29 | 2013-09-25 | Compuestos macrociclicos analogos de sangliferina, inhibidores de la ciclofilina; procedimiento de preparacion; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como infeccion por vhc o vih, o uso como inmunosupresor o agente antiinflamatorio. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013002740A CL2013002740A1 (es) | 2011-03-29 | 2013-09-25 | Compuestos macrociclicos analogos de sangliferina, inhibidores de la ciclofilina; procedimiento de preparacion; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como infeccion por vhc o vih, o uso como inmunosupresor o agente antiinflamatorio. |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US9139613B2 (enExample) |
| EP (2) | EP2691412B1 (enExample) |
| JP (2) | JP6118792B2 (enExample) |
| KR (2) | KR101911484B1 (enExample) |
| CN (3) | CN103619869B (enExample) |
| AR (1) | AR085724A1 (enExample) |
| AU (2) | AU2012235880B2 (enExample) |
| BR (2) | BR112013024965A2 (enExample) |
| CA (2) | CA2830827C (enExample) |
| CL (2) | CL2013002739A1 (enExample) |
| CY (2) | CY1116318T1 (enExample) |
| DK (2) | DK2691413T3 (enExample) |
| EA (2) | EA023848B1 (enExample) |
| ES (2) | ES2533438T3 (enExample) |
| HR (2) | HRP20150187T1 (enExample) |
| IL (2) | IL228508B (enExample) |
| JO (1) | JO3063B1 (enExample) |
| MX (2) | MX345351B (enExample) |
| MY (2) | MY170618A (enExample) |
| PH (2) | PH12013502016A1 (enExample) |
| PL (2) | PL2691412T3 (enExample) |
| PT (2) | PT2691413E (enExample) |
| RS (2) | RS53964B1 (enExample) |
| SG (2) | SG193569A1 (enExample) |
| SI (2) | SI2691412T1 (enExample) |
| TW (1) | TWI525098B (enExample) |
| UY (1) | UY33993A (enExample) |
| WO (2) | WO2012131377A1 (enExample) |
| ZA (2) | ZA201307149B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011098809A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| JO3063B1 (ar) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
| CN103130734A (zh) * | 2011-12-01 | 2013-06-05 | 上海药明康德新药开发有限公司 | 一种合成1,2-吗啉盐酸盐的方法 |
| CN105695541B (zh) * | 2016-03-10 | 2019-03-15 | 苏州华赛生物工程技术有限公司 | 一种抗生素nvp018中间体的分离纯化方法 |
| KR20180036522A (ko) * | 2016-09-30 | 2018-04-09 | (주)나노믹스 | 스틸벤 유도체 및 그 제조 방법 |
| BR112019009903A2 (pt) | 2016-11-18 | 2019-08-13 | Neurovive Pharmaceutical Ab | análogo de sangliferina, combinação, composição farmacêutica, e, método para tratamento de um sujeito sofrendo de câncer ou de malignidade de célula-b |
| CN112410353B (zh) * | 2019-08-23 | 2023-01-24 | 上海医药工业研究院 | 一种fkbS基因、含其的基因工程菌及其制备方法和用途 |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| PE20240088A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN115028681B (zh) * | 2022-08-11 | 2022-11-15 | 中国科学院微生物研究所 | 一种降解亲环素a的嵌合体化合物及其制备方法与应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| RU2427372C2 (ru) | 2005-06-17 | 2011-08-27 | Новартис Аг | Применение санглиферина для лечения вируса гепатита с |
| CN101616683A (zh) | 2007-01-04 | 2009-12-30 | 德比奥法姆股份有限公司 | 用于治疗Ullrich先天性肌营养不良的非免疫抑制性环孢霉素 |
| JP5789190B2 (ja) | 2008-09-24 | 2015-10-07 | シャンハイ インスティテュート オブ オーガニック ケミストリー，チャイニーズ アカデミー オブ サイエンシズ | 新規の遺伝子クラスター |
| CN101691575B (zh) * | 2008-09-24 | 2013-06-05 | 中国科学院上海有机化学研究所 | 一种萨菲菌素的生物合成基因簇 |
| WO2011098809A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| WO2011098805A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| WO2011098808A1 (en) * | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| KR101900974B1 (ko) * | 2010-12-20 | 2018-09-21 | 뉴로바이브 파마슈티컬 에이비 | 상글리페린 유도체 및 이의 제조 방법 |
| JO3063B1 (ar) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
-
2012
- 2012-03-12 JO JOP/2012/0053A patent/JO3063B1/ar active
- 2012-03-28 AR ARP120101043A patent/AR085724A1/es unknown
- 2012-03-28 TW TW101110673A patent/TWI525098B/zh not_active IP Right Cessation
- 2012-03-29 KR KR1020137028095A patent/KR101911484B1/ko not_active Expired - Fee Related
- 2012-03-29 BR BR112013024965A patent/BR112013024965A2/pt not_active Application Discontinuation
- 2012-03-29 JP JP2014501719A patent/JP6118792B2/ja not_active Expired - Fee Related
- 2012-03-29 CN CN201280026190.3A patent/CN103619869B/zh not_active Expired - Fee Related
- 2012-03-29 JP JP2014501720A patent/JP6118793B2/ja active Active
- 2012-03-29 SG SG2013070974A patent/SG193569A1/en unknown
- 2012-03-29 PH PH1/2013/502016A patent/PH12013502016A1/en unknown
- 2012-03-29 AU AU2012235880A patent/AU2012235880B2/en not_active Ceased
- 2012-03-29 US US14/006,341 patent/US9139613B2/en active Active
- 2012-03-29 CA CA2830827A patent/CA2830827C/en not_active Expired - Fee Related
- 2012-03-29 KR KR1020137027773A patent/KR101868084B1/ko not_active Expired - Fee Related
- 2012-03-29 US US13/433,944 patent/US9090657B2/en active Active
- 2012-03-29 PT PT127165397T patent/PT2691413E/pt unknown
- 2012-03-29 HR HRP20150187TT patent/HRP20150187T1/hr unknown
- 2012-03-29 DK DK12716539T patent/DK2691413T3/en active
- 2012-03-29 AU AU2012235961A patent/AU2012235961B2/en not_active Ceased
- 2012-03-29 MX MX2013011043A patent/MX345351B/es active IP Right Grant
- 2012-03-29 SI SI201230145T patent/SI2691412T1/sl unknown
- 2012-03-29 CN CN201280026793.3A patent/CN103635484B/zh not_active Expired - Fee Related
- 2012-03-29 PL PL12716538T patent/PL2691412T3/pl unknown
- 2012-03-29 SG SG2013070966A patent/SG193568A1/en unknown
- 2012-03-29 RS RS20150162A patent/RS53964B1/sr unknown
- 2012-03-29 MX MX2013011051A patent/MX345352B/es active IP Right Grant
- 2012-03-29 ES ES12716539.7T patent/ES2533438T3/es active Active
- 2012-03-29 WO PCT/GB2012/050707 patent/WO2012131377A1/en not_active Ceased
- 2012-03-29 CA CA2830831A patent/CA2830831C/en not_active Expired - Fee Related
- 2012-03-29 EP EP12716538.9A patent/EP2691412B1/en active Active
- 2012-03-29 PT PT127165389T patent/PT2691412E/pt unknown
- 2012-03-29 CN CN201611126823.4A patent/CN107417766A/zh active Pending
- 2012-03-29 EA EA201391399A patent/EA023848B1/ru not_active IP Right Cessation
- 2012-03-29 HR HRP20150184TT patent/HRP20150184T1/hr unknown
- 2012-03-29 EP EP12716539.7A patent/EP2691413B1/en active Active
- 2012-03-29 ES ES12716538.9T patent/ES2533437T3/es active Active
- 2012-03-29 UY UY0001033993A patent/UY33993A/es not_active Application Discontinuation
- 2012-03-29 PH PH1/2013/502000A patent/PH12013502000B1/en unknown
- 2012-03-29 EA EA201391396A patent/EA023907B1/ru not_active IP Right Cessation
- 2012-03-29 SI SI201230146T patent/SI2691413T1/sl unknown
- 2012-03-29 MY MYPI2013701789A patent/MY170618A/en unknown
- 2012-03-29 RS RS20150161A patent/RS53963B1/sr unknown
- 2012-03-29 WO PCT/GB2012/050700 patent/WO2012131371A1/en not_active Ceased
- 2012-03-29 PL PL12716539T patent/PL2691413T3/pl unknown
- 2012-03-29 MY MYPI2013701788A patent/MY170637A/en unknown
- 2012-03-29 DK DK12716538T patent/DK2691412T3/en active
- 2012-03-29 BR BR112013024974A patent/BR112013024974A2/pt not_active Application Discontinuation
-
2013
- 2013-09-17 IL IL228508A patent/IL228508B/en active IP Right Grant
- 2013-09-17 IL IL228509A patent/IL228509B/en active IP Right Grant
- 2013-09-23 ZA ZA2013/07149A patent/ZA201307149B/en unknown
- 2013-09-25 CL CL2013002739A patent/CL2013002739A1/es unknown
- 2013-09-25 CL CL2013002740A patent/CL2013002740A1/es unknown
- 2013-09-26 ZA ZA2013/07231A patent/ZA201307231B/en unknown
-
2015
- 2015-02-27 CY CY20151100207T patent/CY1116318T1/el unknown
- 2015-03-06 CY CY20151100236T patent/CY1116186T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2012000243A (es) | Compuestos de sililo tricíclicos fusionados y uso de los mismos en la fabricación de medicamentos útiles en el tratamiento de enfermedades virales | |
| UY32490A (es) | Inhibidores de beta-secretasa | |
| PY1153144A (es) | Inhibidores macrocíclicos de virus flaviviridae | |
| ECSP12012067A (es) | Inhibidores del virus de la hepatitis c | |
| WO2010084115A3 (en) | Antiviral agents | |
| CO6470846A2 (es) | Derivados aminobut´ricos sustituidos como inhibidores de neprilisina | |
| MX2020008468A (es) | Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas. | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| DOP2014000121A (es) | Derivados de betulina | |
| CO6561783A2 (es) | Inhibidores del virus flaviviridae | |
| DOP2015000079A (es) | Análogos de 2'-cloro nucleósido para infección por vhc | |
| UY32174A (es) | Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones | |
| MX2012015292A (es) | Pirazolo[1, 5]pirimidinas en la forma de agentes antivirales. | |
| CR20130560A (es) | Compuestos de bezotiazol y su uso farmacéutico | |
| ECSP12011684A (es) | Inhibidores de los virus flaviviridae. | |
| DOP2011000343A (es) | Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral | |
| CO6470847A2 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| CO6620055A2 (es) | Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos | |
| BR112016010080A8 (pt) | compostos de pirazolopirimidina, composição farmacêutica e seu uso | |
| GT201200158A (es) | Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para su uso como principio activo farmacéutico | |
| MX2012006297A (es) | Uso topico hidroxitirosol y derivados para la prevencion de la infeccion por vih. | |
| ECSP13012812A (es) | Formulaciones inmunosupresoras | |
| IN2012DN01855A (enExample) | ||
| AR085724A1 (es) | ANALOGO DE LA SANGLIFERINA CON ACTIVIDAD INHIBIDORA DE mPTP | |
| EA201490222A1 (ru) | Комбинированные составы на основе дарунавира |